Evidence map›Paper›PMID 24718703›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2014

Liver tumor promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxin is dependent on the aryl hydrocarbon receptor and TNF/IL-1 receptors.

Gregory D Kennedy, Manabu Nukaya, Susan M Moran, Edward Glover, Samuel Weinberg, Silvia Balbo, Stephen S Hecht, Henry C Pitot, Norman R Drinkwater, Christopher A Bradfield

Open access · bronzeAbstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Generation of an Allelic Series at the Ahr Locus Using an Edited Recombinant Approach.Toxicological sciences : an official journal of the Society of Toxicology · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Gregory D KennedyDepartment of Surgery, University of Wisconsin, School of Medicine and Public Health, Madison, Wisconsin 53792.
Manabu NukayaDepartment of Surgery, University of Wisconsin, School of Medicine and Public Health, Madison, Wisconsin 53792.
Susan M MoranMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin 53706.
Edward GloverMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin 53706.
Samuel WeinbergMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin 53706.
Silvia BalboMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455.
Stephen S HechtMasonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455.
Henry C PitotMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin 53706.
Norman R DrinkwaterMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin 53706.
Christopher A BradfieldMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, School of Medicine and Public Health, Madison, Wisconsin 53706 bradfield@oncology.wisc.edu.
University of Wisconsin–Madison · USUniversity of Minnesota Medical Center · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Training Program In Lung SciencesT32HL076139 · NHLBI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KAREN M RIDGE, Jacob I Sznajder · 2004 to 2026
$9.6M
TRANSGENIC MODELS OF DIOXIN CARCINOGENICITY AND AH RECEPTOR FUNCTIONP01CA022484 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI BRADFIELD, CHRISTOPHER A · 1985 to 2011
$9.2M
Transgenic Models of Ah Receptor ActionR01ES020668 · NIEHS · UNIVERSITY OF WISCONSIN-MADISON · PI BRADFIELD, CHRISTOPHER A · 2012 to 2016
$1.7M
Genetic Insight Into AH Receptor-Mediated Promotion Of HepatocarcinogenesisK08ES017283 · NIEHS · UNIVERSITY OF WISCONSIN-MADISON · PI KENNEDY, GREGORY DEAN · 2009 to 2013
$777k
NCI NIH HHS P01-CA-022484NCI NIH HHS P30 CA014520NCI NIH HHS P30-CA-014520NHLBI NIH HHS T32 HL076139NIEHS NIH HHS K08-ES-017283NIEHS NIH HHS R01 ES020668
6 · The paper itself

Abstract

We set out to better understand the signal transduction pathways that mediate liver tumor promotion by 2,3,7,8-tetrachlorodibenzo-p-dioxn ("dioxin"). To this end, we first employed congenic mice homozygous for either the Ahr(b1) or Ahr(d) alleles (encoding an aryl hydrocarbon receptor (AHR) with high or low binding affinity for dioxin, respectively) and demonstrated that hepatocellular tumor promotion in response to dioxin segregated with the Ahr locus. Once we had genetic evidence for the importance of AHR signaling, we then asked if tumor promotion by dioxin was influenced by "interleukin-1 (IL-1)-like" inflammatory cytokines. The importance of this question arose from our earlier observation that aspects of the acute hepatocellular toxicity of dioxin are dependent upon IL1-like cytokine signaling. To address this issue, we employed a triple knock-out (TKO) mouse model with null alleles at the loci encoding the three relevant receptors for tumor necrosis factors α and β and IL-1α and IL-1β (i.e., null alleles at the Tnfrsf1a, Tnfrsf1b, and Il-1r1 loci). The observation that TKO mice were resistant to the tumor promoting effects of dioxin in liver suggests that inflammatory cytokines play an important step in dioxin mediated liver tumor promotion in the mouse. Collectively, these data support the idea that the mechanism of dioxin acute hepatotoxicity and its activity as a promoter in a mouse two stage liver cancer model may be similar, i.e., tumor promotion by dioxin, like acute hepatotoxicity, are mediated by the linked action of two receptor systems, the AHR and the receptors for the "IL-1-like" cytokines.

Indexed as

CocarcinogenesisAnimalsCaprylatesDiethylnitrosamineDioxinsLiver Neoplasms, ExperimentalMaleMice, Inbred C57BLMice, KnockoutReceptors, Aryl HydrocarbonReceptors, Interleukin-1Receptors, Tumor Necrosis FactorTriglycerides2,3,7,8-tetrabromodibenzo-4-dioxinCaprylatesDiethylnitrosamineDioxinsReceptors, Aryl HydrocarbonReceptors, Interleukin-1Receptors, Tumor Necrosis FactortricaprylinTriglyceridesaryl hydrocarbon receptor (AHR)dioxinIL-1-like cytokinelivertumor promotion

Identifiers

PMID24718703
PMCPMC4133587
OpenAlexW2169354960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.